SecBot SecBot

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

H.R. 8205 Rep. Mike Quigley (D-IL-5) To President
Bill text PDF
  1. Introduced Apr 6
  2. Committee Apr 6
  3. Passed House Jul 22
  4. Passed Senate Sep 28
  5. To President Oct 26
  6. Law Next
Where it stands
To President, Oct 26, 2026Next: Signature
1d ago Oct 26, 2026: Presented to President.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
1company, 2 filings
Subscribe to see spend
Member trades
0trades in the last 90 days
None in these companies
Who the bill helps and hurts Subscribe

Companies lobbying on this bill

1 company
Companies by sector
Biotech & Pharma 1
Search all 1 companies, their asks and price moves Subscribe

Summary

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Full summary7 paragraphs

This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.

The bill reauthorizes

- grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,

- grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and

- a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.

Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs.

Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

Library of Congress summary, Jul 9, 2026

Summary versions
  • Reported to HouseJul 9, 2026

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 27, 2026.